Eyenovia to present Phase 3 clobtasol study results at AAO 2024 Expo

Eyenovia announced a presentation at the American Academy of Ophthalmology 2024 Expo, which is being held October 19-21, in Chicago. The presentation will detail the results of a Phase 3 study of clobetasol propionate suspension 0.05% that led to its approval by the U.S. Food and Drug Administration as a treatment for inflammation and pain following ocular surgery. Eyenovia announced the U.S. launch and commercial availability of clobetasol on September 26, 2024. “We are very pleased to see the results from this successful Phase 3 study of clobetasol presented at this year’s AAO Expo,” stated Michael Rowe, Chief Executive Officer of Eyenovia. “The results demonstrated the magnitude and speed of inflammation and pain relief as soon as four days post-surgery as compared to placebo, with a more rapid improvement in visual acuity and a desirable safety profile.”